Noticias de Eulerpool NLS Pharmaceutics

NLS Pharmaceutics Noticias de Acciones

NLS Pharmaceutics es observado por muchos periodistas e inversores en todo el mundo. Aquí recopilamos las noticias más recientes de NLS Pharmaceutics.

• 30 de junio ·

  Yahoo
  NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing
• 16 de junio ·

  Yahoo
  NLS Pharmaceutics CEO Issues Letter to Shareholders
• 21 de mayo ·

  Yahoo
  NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting
• 10 de febrero ·

  Yahoo
  NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies
• 30 de enero ·

  Yahoo
  NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting
• 8 de enero ·

  Yahoo
  NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Share Price as of Jan 6, 2025
• 30 de diciembre ·

  Yahoo
  NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger
• 19 de diciembre ·

  Yahoo
  NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment
• 12 de diciembre ·

  Yahoo
  NLS Pharmaceutics expects to close Kadimastem merger by end of January
• 3 de diciembre ·

  Yahoo
  NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders